Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
复制标题
利培酮对智商低于平均水平的儿童的行为和破坏性行为障碍的影响。
DOI：
--
复制
发表时间：
2002
影响因子：
13.3
通讯作者：
A. Carroll
中科院分区：
文献类型：
--
作者：
R. Snyder;A. Turgay;M. Aman;C. Binder;S. Fisman;A. Carroll
目的
确定利培酮是否能有效减少与品行障碍、对立违抗性障碍和破坏性行为障碍相关的破坏性行为（如攻击性、冲动性、蔑视权威人物和破坏财产）的症状，这些行为障碍在智商低于平均水平的儿童中未另作说明。
方法
试验包括1周、单盲、安慰剂导入期，随后是6周、双盲、安慰剂对照期。入组了110名儿童（年龄5-12岁，含），智商为36-84，患有破坏性行为障碍，Nisonger儿童行为评定表（NCBRF）的行为问题子量表评分至少为24分。80%的受试者患有共病的注意力缺陷/多动障碍（ADHD）。利培酮剂量范围为0.02 - 0.06 mg/kg/天。受试者接受NCBRF、异常行为检查表、行为问题量表、临床整体印象量表（CGI）、改良加州言语学习测验（CVLT）和持续执行任务（CPT）评分。
结果
意向治疗分析显示，利培酮治疗受试者的NCBRF行为问题子量表的平均评分（从基线时的33.4降至终点时的17.6;降低47.3%）与安慰剂治疗受试者（基线时的平均32.6降至终点时的25.8;降低20.9%）相比显著降低（p <0.001）。利培酮组间差异早在第1周就已出现，且在所有基线后访视时均具有显著性。与安慰剂相比，利培酮的其他分量表显示出显著改善。CGI量表的改善评级显示利培酮相对于安慰剂具有非常显著的增益。亚组分析表明，利培酮的作用不受诊断，存在/不存在ADHD，精神兴奋剂的使用，IQ状态和嗜睡的影响。利培酮对认知变量（CPT/改良CVLT）无影响。最常见的副作用包括嗜睡、头痛、食欲增加和消化不良。利培酮组和安慰剂组分别有7例（13.2%）和3例（5.3%）受试者报告了与锥体外系症状相关的副作用（p = 0.245）。
结论
利培酮似乎是一个充分耐受和有效的治疗儿童低于平均智商和严重的破坏性行为，如侵略和破坏性行为。
OBJECTIVE
To determine whether risperidone is effective in reducing symptoms of disruptive behaviors (such as aggression, impulsivity, defiance of authority figures, and property destruction) associated with conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified in children with subaverage IQs.
METHOD
The trial consisted of a 1-week, single-blind, placebo run-in period and was followed by a 6-week, double-blind, placebo-controlled period. One hundred ten children (aged 5-12 years inclusive) with an IQ of 36-84 with a disruptive behavior disorder and a score of at least 24 on the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (NCBRF) were enrolled. Eighty percent of subjects had comorbid attention-deficit/hyperactivity disorder (ADHD). Risperidone doses ranged from 0.02 to 0.06 mg/kg per day. Subjects were rated on the NCBRF, Aberrant Behavior Checklist, Behavior Problems Inventory, Clinical Global Impressions (CGI), modified California Verbal Learning Test (CVLT), and a continuous performance task (CPT).
RESULTS
The intention-to-treat analysis of risperidone-treated subjects showed a significant (p < .001) reduction in mean scores (from 33.4 at baseline to 17.6 at end point; 47.3% reduction) versus placebo-treated subjects (mean baseline of 32.6 to 25.8 at end point; 20.9% reduction) on the Conduct Problem subscale of the NCBRF. Between-group differences in favor of risperidone were seen as early as week 1 and were significant at all post-baseline visits. Other subscales showed significant improvement with risperidone compared with placebo. CGI scale ratings of improvement showed highly significant gains for risperidone over placebo. A subanalysis demonstrated that the effect of risperidone was unaffected by diagnosis, presence/absence of ADHD, psychostimulant use, IQ status, and somnolence. Risperidone produced no changes on the cognitive variables (CPT/modified CVLT). The most common side effects included somnolence, headache, appetite increase, and dyspepsia. Side effects related to extrapyramidal symptoms were reported in 7 (13.2%) and 3 (5.3%) of the subjects in the risperidone and placebo groups, respectively (p = .245).
CONCLUSIONS
Risperidone appears to be an adequately tolerated and effective treatment in children with subaverage IQs and severe disruptive behaviors such as aggression and destructive behavior.
对发育障碍人士行为问题的药物治疗进行功能分析。
DOI：
--
发表时间：
1994
期刊：
American journal of mental retardation : AJMR
影响因子：
--
作者：
Schaal,DW;Hackenberg,T
通讯作者：
Hackenberg,T
尼松格儿童行为评级表：年龄和性别影响和规范。
影响因子：
3.1
作者：
Tasse,MJ;Aman,MG;Hammer,D;Rojahn,J
通讯作者：
Rojahn,J